January 17, 2023 7:45am

Post market holiday, positive session closes as gains came on the back of inflation-related data and upcoming Q4 earnings reporting

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth! Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.25% or (-86 points), S&P futures are DOWN -0.16% or (-6 point) and NASDAQ futures are DOWN -0.20% or (-23 points) early in the pre-open – so far

Stock futures traded lower Tuesday,

European markets were flat,

Asia-Pacific markets mostly traded up.



We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Friday, the Dow closed UP +112.64 points (+0.33%), the S&P closed UP +15.91 points (+0.40%) while the Nasdaq closed UP +78.05 points (+0.71%)

The S&P and Nasdaq each posted their second consecutive positive week and best weekly performance since November, the Nasdaq rose +4.82%, the S&P advanced 2.67%, and the Dow added 2%.


Friday’s (1/13) … RegMed Investors’ (RMi) closing bell: “cell/gene therapy sector wavers paring upside yet closes scarcely positive. I started the a.m. post the title, “vulnerable after a surge, there is usually a purge”. Cautious optimism is the bye-word for Q4 and FY22 reporting season looms with some companies reporting un-audited numbers to prop share pricing. Remember Monday is a market holiday.” … https://www.regmedinvestors.com/articles/12786


Ebb and flow:

Q1/23 – 2 holiday, 6 positive and 3 negative closes


·         December – 1 holiday, 13 negative and 8 positive closes

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

None - after a surge, there is usually a purge


The BOTTOM LINE: I try to keep it simple and short!

On Friday of last week, we closed at the lowest level for the VIX index all year long through 2022. And what does that indicate - complacency

Four (4) sector positive closes in a row as the Nasdaq, which has been a laggard in recent months watch-out below.

My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday

Reiterating, “As 2023 trading begins, some investors think the pain is far from over; I agree for Q1 as Q4 earnings releases could hinder share pricing however, once through that “gauntlet” – we could see a bit of a smoother road in Q2/2023 hoping for a few clinical results and successful financings – well needed for more than usual companies.”

“Don't act like the market is in an uptrend until the market is actually in an uptrend”.

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment,


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.